This product is an oral hypoglycemic drug. Its mechanism of hypoglycemic effect is to inhibit the activity of a-glucosidase in the small intestinal wall cells, delay the degradation of ingested carbohydrates, and thus reduce postprandial blood sugar levels.

This product is a biosynthesized pseudotetrasaccharide. Animal test results show that this product has an inhibitory effect on the activity of α-glucosidase in the brush border of small intestinal wall cells, thereby delaying the degradation of polysaccharides, oligosaccharides or disaccharides in the intestine, slowing down the degradation and absorption of glucose from carbohydrates into the blood, reducing the increase in blood sugar after meals, and lowering the average blood sugar value.

Cyclosporine is a new type of T lymphocyte regulator that can specifically inhibit the activity of helper T lymphocytes, but does not inhibit T lymphocytes, but promotes their proliferation. This product can also inhibit the activity of B lymphocytes: this product can also selectively inhibit interleukin-2 and interferon-β secreted by T lymphocytes, and can also inhibit interleukin-1 secreted by monocytes and phagocytes. While significantly inhibiting host cell immunity, it also has an inhibitory effect on humoral immunity. It can inhibit the production of anti-graft antibodies in the body, and thus has an anti-rejection effect. This product does not affect the function of phagocytes and does not produce obvious bone marrow suppression.

Cyclosporine is a new type of T lymphocyte regulator that can specifically inhibit the activity of helper T lymphocytes, but does not inhibit T lymphocytes, but promotes their proliferation. This product can also inhibit the activity of B lymphocytes: this product can also selectively inhibit interleukin-2 and interferon-β secreted by T lymphocytes, and can also inhibit interleukin-1 secreted by monocytes and phagocytes. While significantly inhibiting host cell immunity, it also has an inhibitory effect on humoral immunity. It can inhibit the production of anti-graft antibodies in the body, and thus has an anti-rejection effect. This product does not affect the function of phagocytes and does not produce obvious bone marrow suppression.

Cyclosporine is a potent immunosuppressant that acts reversibly and specifically on lymphocytes. It can prolong the survival time of allogeneic organ transplants, inhibit cell-mediated immune responses, inhibit the synthesis and release of lymphokines (including IL-2), and block the G0 phase and early G1 phase of the lymphocyte growth cycle. It does not inhibit erythropoiesis and does not affect phagocyte function. Patients using this product have a lower incidence of infection than those using other immunosuppressants.